Myelin lesions associated with lysosomal and peroxisomal disorders

Expert Review of Neurotherapeutics

Volumn 10, Issue 9, 2010, Pages 1449-1466

  Faust, Phyllis L ^a   Kaye, Edward M ^b   Powers, James M ^c  

^a NewYork Presbyterian Hospital   (United States)

^b GENZYME CORPORATION   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

adreno leukodystrophy; bone marrow transplant; gene therapy; globoid cell (Krabbes) and metachromatic leukodystrophy; lipid toxicity; lysosomal storage; microglial cells; neuroinflammation; oxidative stress; very long chain fatty acids

Indexed keywords

ANTIOXIDANT; CYCLOSERINE; ISOFLAVONE; LIPID; LORENZO OIL; MYELIN; RECOMBINANT PROTEIN; VERY LONG CHAIN FATTY ACID; VIRUS VECTOR;

ADRENOLEUKODYSTROPHY; BONE MARROW TRANSPLANTATION; CADASIL; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; DEMYELINATING DISEASE; DEMYELINATION; DIET RESTRICTION; DISEASE ASSOCIATION; ENZYME DEFICIENCY; GENE MUTATION; GENE THERAPY; GLOBOID CELL LEUKODYSTROPHY; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; LIFESPAN; LYSOSOME; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEWBORN SCREENING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; ONSET AGE; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM; PEROXISOME; REVIEW; TRANSGENIC MOUSE; TREATMENT OUTCOME; WHITE MATTER;

ANIMALS; HUMANS; LEUKODYSTROPHY, METACHROMATIC; LYSOSOMES; MYELIN SHEATH; PEROXISOMAL DISORDERS;

EID: 77956474275     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.127     Document Type: Review

References (128)

1. Powers, JM. The leukodystrophies: overview and classifcation. In: Myelin Biology and Disorders (Volume 2). Lazzarini RA (Ed.). Elsevier Academic Press, CA, USA, 663-690 (2004)
2. rd Edition). Springer, NY, USA (2005).
3. De Duve C. The lysosome turns ffty. Nat. Cell Biol. 7(9), 847-849 (2005).
4. Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histol. Histopathol. 25(1), 99-112 (2010).
5. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 132(1), 27-42 (2008).
6. Walkley SU. Pathogenic cascades in lysosomal disease-why so complex? J. Inherit. Metab. Dis. 32(2), 181-189 (2009).
7. Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta. 1793(4), 684-696 (2009).
8. Jalanko A, Braulke T Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta 1793(4), 697-709 (2009).
9. Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: traffcking meets function. Nat. Rev. Mol. Cell. Biol. 10(9), 623-635 (2009).
10. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase defciency, mucolipidosis II/III and Niemann-Pick C1 disease-lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim. Biophys. Acta. 1793(4), 710-725 (2009).
11. Walkley SU, Vanier MT Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta 1793(4), 726-736 (2009).
12. Polo S, Di Fiore PP. Endocytosis conducts the cell signaling orchestra. Cell 124(5), 897-900 (2006).
13. Tettamanti G, Bassi R, Viani P, Riboni L. Salvage pathways in glycosphingolipid metabolism. Biochemie 85(3-4), 432-437 (2003).
14. Van Der Voorn JP, Kamphorst W, van der Knaap MS, Powers JM. The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction. Acta Neuropathol 107(6), 539-545 (2004).
15. Suzuki K, Suzuki K. Lysosomal diseases. In: Greenfeld's Neuropathology (8th Edition). Love S, Louis DN, Ellison DW (Eds). Hodder Arnold, London, UK, 515-599 (2008).
16. Cesani M, Capotondo A, Plati T et al. Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy. Hum. Mutat. 30(10), E936-E945 (2009).
17. Hess B, Saftig P, Hartmann D et al. Phenotype of arylsulfatase A-defcient mice: relationship to human metachromatic leukodystrophy. Proc. Natl Acad. Sci. USA 93(25), 14821-14826 (1996).
18. Sun Y, Witte DP, Ran H et al. Neurological defcits and glycosphingolipid accumulation in saposin B defcient mice. Hum. Mol. Genet. 17(15), 2345-2356 (2008).
19. Saravanan K, Schaeren-Wiemers N, Klein D et al. Specifc downregulation and mistargeting of the lipid raft-associated protein MAL in a glycolipid storage disorder. Neurobiol. Dis. 16(2), 396-406 (2004).
20. Klein D, Yaghootfam A, Matzner U et al Mannose 6-phosphate receptor-dependent endocytosis of lysosomal enzymes is increased in sulfatide-storing kidney cells. Biol. Chem. 390(1), 41-48 (2009).
21. Tempesta MC, Salvayre R, Levade T Functional compartments of sulphatide metabolism in cultured living cells: evidence for the involvement of a novel sulphatide-degrading pathway. Biochem. J. 297(3), 479-489 (1994).
22. Eckhardt M, Hedayati KK, Pitsch J et al Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy. J. Neurosci. 27(34), 9009-9021 (2007).
23. Ramakrishnan H, Hedayati KK, Lüllmann-Rauch R et al. Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-defcient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J. Neurosci. 27(35), 9482-9490 (2007).
24. Wenger DA, Raf MA, Luzi P, Datto J, Costantino-Ceccarini E. Krabbe disease: genetic aspects and progress toward therapy. Mol. Genet. Metab. 70(1), 1-9 (2000).
25. Xu C, Sakai N, Taniike M, Inui K, Ozono K. Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation. J. Hum. Genet. 51(6), 548-554 (2006).
26. Giri S, Jatana M, Rattan R, Won JS, Singh I, Singh AK. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J. 16(7), 661-672 (2002).
27. Castaneda JA, Lim MJ, Cooper JD, Pearce DA. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 115(2), 159-174 (2008).
28. Wenger DA. Murine, canine and non-human primate models of Krabbe disease. Mol. Med. Today 6(11), 449-451 (2000).
29. Suzuki K, Taniike M. Murine model of genetic demyelinating disease: the twitcher mouse. Microsc. Res. Tech. 32(3), 204-214 (1995).
30. Giri S, Khan M, Nath N, Singh I, Singh AK. The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem. 105(5), 1820-1833 (2008).
31. White AB, Givogri MI, Lopez-Rosas A et al. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J. Neurosci. 29(19), 6068-6077 (2009).
32. Matsuda J, Yoneshige A, Suzuki K. The function of sphingolipids in the nervous system: lessons learnt from mouse models of specifc sphingolipid activator protein defciencies. J. Neurochem. 103(Suppl. 1), 32-38 (2007).
33. Wanders RJA, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu. Rev. Biochem. 75, 295-332 (2006).
34. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW Peroxisome biogenesis disorders. Biochim. Biophys. Acta 1763(12), 1733-1748 (2006).
35. Wanders RJ, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme defciencies. Biochim. Biophys. Acta 1763(12), 1707-1720 (2006).
36. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat. Clin. Pract. Neurol. 3(3), 140-151 (2007).
37. Ferdinandusse S, Denis S, Mooyer PA et al. Clinical and biochemical spectrum of D-bifunctional protein defciency. Ann. Neurol. 59(1), 92-104 (2006).
38. Ferdinandusse S, Ylianttila MS, Gloerich J et al. Mutational spectrum of D-bifunctional protein defciency and structure-based genotype-phenotype analysis. Am. J. Hum. Genet. 78(1), 112-124 (2006).
39. Wanders RJ, Ferdinandusse S, Brites P, Kemp S. Peroxisomes, lipid metabolism and lipotoxicity. Biochim. Biophys. Acta 1801(3), 272-280 (2010).
40. Schrader M, Fahimi HD. Peroxisomes and oxidative stress. Biochim. Biophys. Acta 1763(12), 1755-1766 (2006).
41. Gorgas K, Teigler A, Komljenovic D, Just WW. The ether lipid-defcient mouse: tracking down plasmalogen functions. Biochim. Biophys. Acta 1763(12), 1511-1526 (2006).
42. Ahlemeyer B, Neubert I, Kovacs WJ, Baumgart-Vogt E. Differential expression of peroxisomal matrix and membrane proteins during postnatal development of mouse brain. J. Comp. Neurol. 505(1), 1-17 (2007).
43. Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol. 8(1), 101-120 (1998).
44. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninfammatory myelopathy J. Neuropathol. Exp. Neurol. 59(2), 89-102 (2000).
45. Van Roermund CWT, Visser WF, IJlst L et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J. 22(12), 4201-4208 (2008).
46. Ito M, Blumberg BM, Mock DJ et al Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol Exp. Neurol. 60(10), 1004-1019 (2001).
47. Asheuer M, Bieche I, Laurendeau I et al. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum. Mol. Genet. 14(10), 1293-1303 (2005).
48. Semmler A, Bao X, Cao G et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J. Neurol. 256(8), 1277-1280 (2009).
49. Powers JM. Peroxisomal diseases. In: Greenfeld's Neuropathology (8th Edition). Love S, Louis DN, Ellison DW (Eds). Hodder Arnold, London, UK, 643-673 (2008).
50. Powers JM, Pei Z, Heinzer AK et al Adreno-leukodystrophy: oxidative stress of mice and men. J. Neuropathol. Exp. Neurol 64(12), 1067-1079 (2005).
51. Lu JF, Barron-Casella E, Deering R et al The role of peroxisomal ABC transporters in the mouse adrenal gland: the loss of Abcd2 (ALDR), Not Abcd1 (ALD), causes oxidative damage. Lab. Invest. 87(3), 261-272 (2007).
52. Fourcade S, López-Erauskin J, Galino J et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol Genet. 17(12), 1762-1773 (2008).
53. Powers JM, DeCiero DP, Cox C et al The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J. Neuropathol. Exp. Neurol. 60(5), 493-501 (2001).
54. Höftberger R, Kunze M, Weinhofer I et al Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol. Dis. 28(2), 165-174 (2007).
55. Kassmann CM, Nave KA. Oligodendroglial impact on axonal function and survival-a hypothesis. Curr. Opin. Neurol. 21(3), 235-241 (2008).
56. Baes M, Aubourg P. Peroxisomes, myelination, and axonal integrity in the CNS. Neuro scientist 15(4), 367-379 (2009).
57. Kassmann CM, Lappe-Siefke C, Baes M et al. Axonal loss and neuroinfammation caused by peroxisome-defcient oligodendrocytes. Nat. Genet. 39(8), 969-976 (2007).
58. Hulshagen L, Krysko O, Bottelbergs A et al. Absence of functional peroxisomes from mouse CNS causes dysmyelination and axon degeneration. J. Neurosci. 28(15), 4015-4027 (2008).
59. Brites P, Mooyer PA, El Mrabet L, Waterham HR, Wanders RJ. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 132(Pt 2), 482-492 (2009).
60. Khan M, Singh J, Singh I. Plasmalogen defciency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J. Neurochem. 106(4), 1766-1779 (2008).
61. Huyghe S, Schmalbruch H, Hulshagen L, Veldhoven PV, Baes M, Hartmann D. Peroxisomal multifunctional protein-2 defciency causes motor defcits and glial lesions in the adult central nervous system. Am. J. Pathol. 168(4), 1321-1334 (2006).
62. Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet. Metab. 90(3), 268-276 (2007).
63. Fourcade S, Ruiz M, Camps C et al A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am. J. Physiol. Endocrinol. Metab. 296(1), E211-E221 (2009).
64. Porter MT, Fluharty AL, Kihara H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fbroblasts. Science 172(989), 1263-1265 (1971).
65. Brady RO. Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57, 283-296 (2006).
66. Schröder S, Matthes F, Hyden P et al Site-specifc analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines. Glycobiology 20(2), 248-259 (2010).
67. Krivit W, Shapiro E, Kennedy W et al Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N Engl. J. Med. 322(1), 28-32 (1990).
68. Biff A, Lucchini G, Rovelli A, Sessa M. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant. 42(Suppl. 2), S2-S6 (2008).
69. Orchard PJ, Blazar BR, Wagner J et al Hematopoietic cell therapy for metabolic disease. J. Pediatr. 151(4), 340-346 (2007).
70. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 31(4), 229-239 (2003).
71. Peters C. Hematopoietic stem cell transplantation for storage diseases. In: Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation (4th Edition). Appelbaum FR, Forman SJ, Negrin RS (Eds). Wiley, Oxford, UK, 1136-1162 (2009).
72. Matzner U, Lüllmann-Rauch R, Stroobants S et al. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 17(4), 600-606 (2009).
73. Lagranha VL, Baldo G, de Carvalho TG et al. In vitro correction of ARSA defciency in human skin fbroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells. Metab. Brain Dis. 23(4), 469-484 (2008).
74. Lattanzi A, Neri M, Maderna C et al Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Hum. Mol Genet. 19(11), 2208-2227 (2010).
75. Colle MA, Piguet F, Bertrand L et al Effcient intracerebral delivery of AAV5 vector encoding human ARSA in nonhuman primate. Hum. Mol. Genet. 19(1), 147-158 (2010).
76. Iwamoto N, Watanabe A, Yamamoto M et al. Global diffuse distribution in the brain and effcient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J. Gene Med. 11(6), 498-505 (2009).
77. Biff A, Capotondo A, Fasano S et al Gene therapy of metachromatic leukodystrophy reverses neurological damage and defcits in mice. J. Clin. Invest. 116(11), 3070-3082 (2006).
78. Suzuki K, Suzuki K. The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol. 5(3), 249-258 (1995).
79. Luzi P, Raf MA, Zaka M et al. Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation. Mol. Genet. Metab. 86(1-2), 150-159 (2005).
80. Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage diseases. Drugs 62(5), 733-742 (2002).
81. Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics 118(3), e879-e889 (2006).
82. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant. 41(2), 99-108 (2008).
83. Lim ZY, Ho AY, Abrahams S et al. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplant. 41, 831-832 (2008).
84. Lee WC, Courtenay A, Troendle FJ et al. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J. 19(11), 1549-1551 (2005).
85. Lee WC, Tsoi YK, Troendle FJ et al Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 21(10), 2520-2527 (2007).
86. Raf MA, Zhi Rao H, Passini MA et al. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol. Ther. 11(5), 734-744 (2005).
87. Biswas S, LeVine SM. Substrate-reduction therapy enhances the benefts of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr. Res. 51(1), 40-47 (2002).
88. Luzi P, Abraham RM, Raf MA, Curtis M, Hooper DC, Wenger DA. Effects of treatments on infammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res. 1300, 146-158 (2009).
89. Pannuzzo G, Cardile V, Costantino-Ceccarini E, Alvares E, Mazzone D, Perciavalle V. A galactose-free diet enriched in soy isofavones and antioxidants results in delayed onset of symptoms of Krabbe disease in twitcher mice. Mol. Genet. Metab. 100(3), 234-240 (2010).
90. Moser HW, Tutschka PJ, Brown FR 3rd et al. Bone marrow transplant in adrenoleukodystrophy. Neurology 34(11), 1410-1417 (1984).
91. Aubourg P, Blanche S, Jambaque I et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N. Engl. J. Med. 322, 1860-1866 (1990).
92. Yanagisawa N, Shimada K, Miyazaki T et al. Enhanced production of nitric oxide, reactive oxygen species, and pro-infammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. Lipids Health Dis. 7, 48-57 (2008).
93. Shapiro E, Krivit W, Lockman L et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy Lancet 356(9231), 713-718 (2000).
94. Peters C, Charnas LR, Tan Y et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104(3), 881-888 (2004).
95. Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 6(8), 687-692 (2007).
96. Semmler A, Köhler W, Jung HH, Weller M, Linnebank M. Therapy of X-linked adrenoleukodystrophy. Expert Rev. Neurother. 8(9), 1367-1379 (2008).
97. Drover VA. Adrenoleukodystrophy: recent advances in treatment and disease etiology Clin. Lipidol. 4(2), 205-213 (2009).
98. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954), 818-823 (2009).
99. Moser HW, Raymond GV, Lu SE et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch. Neurol. 62(7), 1073-1080 (2005).
100. Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV. 'Lorenzo's oil' therapy for X-linked adrenoleukodystrophy: rationale and current assessment of effcacy. J. Mol. Neurosci. 33(1), 105-113 (2007).
101. Tolar J, Orchard PJ, Bjoraker KJ, Ziegler RS, Shapiro EG, Charnas L. N-acetyl-L-cysteine improves outcome of advanced cerebral adrenoleukodystrophy. Bone Marrow Transplant. 39(4), 211-215 (2007).
102. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr. Opin. Mol. Ther. 10(5), 471-478 (2008).
103. Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain Dev. 31(7), 485-487 (2009).
104. Kemp S, Valianpour F, Denis S et al. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol. Genet. Metab. 84(2), 144-151 (2005).
105. Ofman R, Dijkstra IM, van Roermund CW et al. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol. Med. 2(3), 90-97 (2010).
106. Taylor RM, Lee JP, Palacino JJ et al. Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy J. Neurochem. 97(6), 1585-1599 (2006).
107. Pellegatta S, Tunici P, Poliani PL et al. The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol. Dis. 21(2), 314-323 (2006).
108. Zhao G, McCarthy NF, Sheehy PA, Taylor RM. Comparison of the behavior of neural stem cells in the brain of normal and twitcher mice after neonatal transplantation. Stem Cells Dev. 16(3), 429-438 (2007).
109. Strazza M, Luddi A, Carbone M et al. Signifcant correction of pathology in brains of twitcher mice following injection of genetically modifed mouse neural progenitor cells. Mol. Genet. Metab. 97(1), 27-34 (2009).
110. Kawabata K, Migita M, Mochizuki H et al. Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres. Brain Res. 1094(1), 13-23 (2006).
111. Klein D, Schmandt T, Muth-Köhne E et al. Embryonic stem cell-based reduction of central nervous system sulfatide storage in an animal model of metachromatic leukodystrophy. Gene Ther. 13(24), 1686-1695 (2006).
112. Givogri MI, Bottai D, Zhu HL et al. Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. Dev. Neurosci. 30(5), 340-357 (2008).
113. Meikle PJ, Grasby DJ, Dean CJ et al. Newborn screening for lysosomal storage disorders. Mol. Genet. Metab. 88(4), 307-314 (2006).
114. Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin. Chem. 56(7), 1071-1079 (2010).
115. Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol. Diagn. Ther. 11(6), 381-384 (2007).
116. Hubbard WC, Moser AB, Liu AC et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol. Genet. Metab. 97(3), 212-220 (2009).
117. Duffner PK, Caggana M, Orsini JJ et al. Newborn screening for Krabbe disease: the New York State model. Pediatr. Neurol 40, 245-252 (2009).
118. Galbiati F, Basso V, Cantuti L et al Autonomic denervation of lymphoid organs leads to epigenetic immune atrophy in a mouse model of Krabbe disease. J. Neurosci. 27(50), 13730-13738 (2007).
119. Plati T, Visigalli I, Capotondo A et al. Development and maturation of invariant NKT cells in the presence of lysosomal engulfment. Eur. J. Immunol. 39(10), 2748-2754 (2009).
120. Wu L, Gabriel CL, Parekh VV, Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73(6), 535-545 (2009).
121. Khan M, Haq E, Giri S, Singh I, Singh AK. Peroxisomal participation in psychosine-mediated toxicity: implications for Krabbe's disease. J. Neurosci. Res. 80(6), 845-854 (2005).
122. Thoms S, Grønborg S, Gärtner J. Organelle interplay in peroxisomal disorders. Trends Mol. Med. 15(7), 293-302 (2009).
123. Miller RH, Bai L. Cellular approaches for stimulating CNS remyelination. Regen. Med. 2(5), 817-829 (2007).
124. Mastroeni R, Bensadoun JC, Charvin D, Aebischer P, Pujol A, Raoul C. Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann. Neurol. 66(1), 117-122 (2009).
125. Fourcade S, Ruiz M, Guilera C et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum. Mol. Genet. 19(10), 2005-2014 (2010).
126. Calzà L, Fernandez M, Giardino L. Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells. J. Mol. Endocrinol. 44(1), 13-23 (2010).
127. Damjanov I. Central nervous system. In: Anderson's Pathology. Damjanov I, Linder J, Anderson WAD (Eds). CRC Press, MO, USA, 2693-2798 (1996)
128. Rosenberg R. Metabolic disease of the nervous system. In: The Clinical Neurosciences. Churchill Livingstone, NY, USA, 447-493 (1983)